Daxor (DXR) vs Fractyl Health (GUTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Daxor (DXR) has outperformed Fractyl Health (GUTS) over the past year, losing 20.0% versus a loss of 74.8%. Daxor is the larger company by market cap ($61.2 million vs $59.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | GUTS |
|---|---|---|
| Share price | $10.49 | $4.47 |
| Market cap | $61.21M | $59.29M |
| 1-day change | +0.24% | +5.67% |
| YTD return | -29.08% | -83.98% |
| 1-year return | -20.03% | -74.82% |
| 5-year return | -7.02% | — |
| P/E ratio (TTM) | 9.53 | — |
| EPS (TTM) | $1.10 | $-10.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.76 | $29.34 |
| 52-week low | $8.56 | $4.14 |
| Distance from 52-week high | -28.96% | -84.76% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +90.75% | +1251.23% |
| Average volume | 17.27K | 156.16K |
| Shares outstanding | 5.84M | 13.26M |
| Employees | — | 100 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXR has outperformed GUTS by 54.8 percentage points over the past year.
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Health Care · Medical/Dental Instruments · 100 employees
DXR vs GUTS FAQ
Which is bigger, Daxor or Fractyl Health?
Daxor (DXR) is larger, with a market capitalization of $61.21M compared with $59.29M for Fractyl Health (GUTS).
Which stock has performed better over the past year, DXR or GUTS?
DXR returned -20.03% over the past 12 months, compared with -74.82% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Daxor and Fractyl Health in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.